Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Measuring hormone cuts antibiotic use in half in pneumonia patients

25.05.2005


Measuring a hormone in the blood can help doctors greatly reduce the number of days pneumonia patients have to take antibiotics to cure their infection, according to a study to be presented at the American Thoracic Society International Conference on May 24.



In the study, pneumonia patients whose level of the hormone procalcitonin was measured during the course of their illness took antibiotics an average of 6 days, compared with 12 days for patients whose procalcitonin levels were not measured. Fifteen percent of patients whose hormone levels were measured did not have to take antibiotics at all, said study co-author Michael Tamm, M.D., Chief of Pulmonary Medicine and Pulmonary Cell Research at University Hospital in Basel, Switzerland.

"Because of concerns about antibiotic resistance, as well as the cost of antibiotics, it’s always better to give fewer antibiotics," Prof. Tamm said.


Many cases of community-acquired pneumonia are caused by bacteria, which require treatment with antibiotics, but some cases are viral, which get better without antibiotics. But doctors don’t like to delay treatment in order to wait for lab results to tell them whether a patient’s pneumonia is bacterial or viral, so they start all patients on antibiotics, Dr. Tamm said. "Once the treatment is started, it is usually continued for 10 to 14 days, because nobody knows when you can stop without a risk for the patient," he said.

Because levels of procalcitonin have been found to be elevated in patients with bacterial infection but not viral infection or other inflammatory diseases, Dr. Tamm and colleagues decided to study whether measuring levels of the hormone could eliminate or reduce antibiotic use in patients with bacterial pneumonia. Results of the blood test that measures procalcitonin levels can be obtained in only one hour, he said.

They studied more than 300 patients with community-acquired pneumonia (pneumonia that is not caught while a patient is in the hospital), and randomly divided them into two groups. Once group was given the standard antibiotic treatment, while the other was first tested for procalcitonin levels. Fifteen percent of those patients had very low procalcitonin levels, and were presumed to have viral pneumonia; they were not given antibiotics. The remaining 85% had high levels and were started on antibiotics. The researchers measured their procalcitonin levels four, six and eight days later, and discontinued their antibiotics if their levels were low.

Patients in the procalcitonin group who started on antibiotic treatment were able to stop after an average of six days. Their course of illness was similar to those patients who received a full course of antibiotics, in terms of their recovery and number of days spent in the hospital. "We showed we were able to cut the number of days patients were on antibiotics in half, without compromising their outcome," Dr. Tamm said.

Jim Augustine | EurekAlert!
Further information:
http://www.thoracic.org/

More articles from Studies and Analyses:

nachricht Win-win strategies for climate and food security
02.10.2017 | International Institute for Applied Systems Analysis (IIASA)

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

The end of pneumonia? New vaccine offers hope

23.10.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>